Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis.
Angiogenesis
Rheumatoid arthritis
Tofacitinib
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
14 08 2021
14 08 2021
Historique:
received:
21
12
2020
accepted:
18
07
2021
entrez:
15
8
2021
pubmed:
16
8
2021
medline:
7
9
2021
Statut:
epublish
Résumé
During rheumatoid arthritis (RA), the angiogenic processes, occurring with pannus-formation, may be a therapeutic target. JAK/STAT-pathway may play a role and the aim of this work was to investigate the inhibiting role of a JAK-inhibitor, tofacitinib, on the angiogenic mechanisms occurring during RA. After ethical approval, JAK-1, JAK-3, STAT-1, STAT-3 and VEGF expression was evaluated on RA-synovial-tissues. In vitro, endothelial cells (ECs), stimulated with 20 ng/ml of VEGF and/or 1 μM of tofacitinib, were assessed for tube formation, migration and proliferation, by Matrigel, Boyden chamber assay and ki67 gene-expression. In vivo, 32 mice received collagen (collagen-induced arthritis (CIA)) and 32 mice PBS (control). At day 19, CIA and controls mice were divided: 16 mice receiving vehicle and 16 mice receiving tofacitinib. At day 35, the arthritis score, the thickness of paw joints and the serum levels of VEGF and Ang-2 were evaluated. The expression of JAK-1, JAK-3, STAT-1, STAT-3 and VEGF in synovial tissue of RA-patients were significantly higher than healthy controls. In vitro, tofacitinib inhibited the ECs ability to form vessels, to proliferate and to migrate. In vivo, administration of tofacitinib prevented the increase of the arthritis score, the paw thickness, the synovial vessels and VEGF and Ang-2 serum-accumulation, when compared to CIA without tofacitinib. We explored the anti-angiogenic role of tofacitinib, reporting its ability to inhibit in vitro the angiogenic mechanisms of ECs and in vivo the formation of new synovial vessels, occurring in CIA model. These findings suggest that the therapeutic effect of tofacitinib during RA may be also related to its anti-angiogenic activity.
Identifiants
pubmed: 34391476
doi: 10.1186/s13075-021-02587-8
pii: 10.1186/s13075-021-02587-8
pmc: PMC8364029
doi:
Substances chimiques
Piperidines
0
Pyrimidines
0
Pyrroles
0
tofacitinib
87LA6FU830
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
213Informations de copyright
© 2021. The Author(s).
Références
Arthritis Res Ther. 2019 Aug 2;21(1):183
pubmed: 31375130
Ann Rheum Dis. 2001 Nov;60 Suppl 3:iii71-4
pubmed: 11890660
Arthritis Res Ther. 2008;10(1):R14
pubmed: 18234077
Oncogene. 2015 Jun 11;34(24):3107-19
pubmed: 25151964
Angiogenesis. 2017 May;20(2):185-204
pubmed: 28361267
Int J Cancer. 2011 Nov 15;129(10):2502-11
pubmed: 21207415
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Exp Mol Med. 2008 Oct 31;40(5):479-85
pubmed: 18985005
Expert Opin Pharmacother. 2017 Oct;18(14):1525-1533
pubmed: 28829236
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Ann Rheum Dis. 2016 Jan;75(1):311-5
pubmed: 26353790
Lancet. 2017 Jul 29;390(10093):457-468
pubmed: 28629665
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
J Crohns Colitis. 2020 Aug 18;:
pubmed: 32808031
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11205-10
pubmed: 12163646
Angiogenesis. 2015 Oct;18(4):433-48
pubmed: 26198292
Autoimmun Rev. 2011 Aug;10(10):595-8
pubmed: 21545851
Cancer Biol Ther. 2008 Dec;7(12):1994-2003
pubmed: 18981713
Oncol Rep. 2019 Jun;41(6):3219-3232
pubmed: 31002364
Oncotarget. 2016 Nov 22;7(47):76793-76805
pubmed: 27732937
N Engl J Med. 2012 Aug 9;367(6):495-507
pubmed: 22873530
J Immunol. 2010 May 1;184(9):5298-307
pubmed: 20363976
Nat Rev Mol Cell Biol. 2006 May;7(5):359-71
pubmed: 16633338
Autoimmun Rev. 2017 Jun;16(6):594-601
pubmed: 28414154
Drugs. 2017 Apr;77(5):521-546
pubmed: 28255960
Circ Res. 1998 Aug 10;83(3):233-40
pubmed: 9710115
J Biol Chem. 2003 Oct 10;278(41):40026-31
pubmed: 12874294
J Pharmacol Exp Ther. 2014 Jan;348(1):165-73
pubmed: 24218541
Eur J Immunol. 2009 Aug;39(8):2040-4
pubmed: 19672892
PLoS One. 2014 Jan 03;9(1):e82088
pubmed: 24404127
Hosp Pharm. 2013 May;48(5):413-24
pubmed: 24421498
Ann Rheum Dis. 2017 Jun;76(6):960-977
pubmed: 28264816
Front Oncol. 2018 Jul 31;8:287
pubmed: 30109213
Rheumatology (Oxford). 2019 Jun 1;58(6):1122
pubmed: 30698756
J Immunol Res. 2018 Nov 21;2018:8410182
pubmed: 30584543
J Immunol. 2011 Apr 1;186(7):4234-43
pubmed: 21383241
Ann Rheum Dis. 2021 Mar 24;:
pubmed: 33762266
Arthritis Rheumatol. 2018 Dec;70(12):1959-1970
pubmed: 29790294
Ann Intern Med. 2013 Aug 20;159(4):253-61
pubmed: 24026258
Drugs. 2017 Dec;77(18):1987-2001
pubmed: 29139090
PLoS One. 2011;6(8):e23540
pubmed: 21858161
Circulation. 2018 May 1;137(18):1934-1948
pubmed: 29254929
Nat Protoc. 2007;2(5):1269-75
pubmed: 17546023
Cancer Cell Int. 2018 Aug 13;18:110
pubmed: 30123088
Clin Exp Rheumatol. 2016 Mar-Apr;34(2):318-28
pubmed: 26966791
J Inflamm (Lond). 2010 Aug 11;7:41
pubmed: 20701804
Int J Rheum Dis. 2014 May;17(4):369-83
pubmed: 24467605
J Cell Physiol. 2000 Mar;182(3):311-22
pubmed: 10653597
Autoimmun Rev. 2019 May;18(5):501-509
pubmed: 30844558
Arthritis Res Ther. 2018 Aug 29;20(1):196
pubmed: 30157949
Nat Rev Rheumatol. 2016 Jul;12(7):385-97
pubmed: 27225300
Cell Prolif. 2017 Feb;50(1):
pubmed: 27667148
Ann Rheum Dis. 2015 Jun;74(6):1311-6
pubmed: 25398374
Autoimmun Rev. 2019 Oct;18(10):102369
pubmed: 31404701
Arthritis Rheum. 2010 Aug;62(8):2283-93
pubmed: 20506481
Adv Clin Exp Med. 2016 Jul-Aug;25(4):709-17
pubmed: 27629845